In the specific context of triple-negative breast cancer (TNBC), the search for potential therapeutic targets has led to the study of receptor tyrosine kinases (RTKs), such as epidermal growth factor receptor (EGFR) and hepatocyte growth factor receptor (c-Met), which are often overexpressed in TNBC tumors and associated with poor prognosis [14,17,72]. The gene discussed is MET; the disease is triple-negative breast carcinoma.